EndoSpan

About

Funding history · 5 rounds · $60.0M total

Headcount over time

Q&A

What is Endospan's primary business?

Endospan is an Israeli medical device company that develops low-profile stent graft systems for treating aneurysms and dissections throughout the aorta, including the NEXUS® Aortic Arch Stent Graft System.

When was Endospan acquired and by whom?

Endospan was acquired by Artivion, Inc. in May 2026 for an amount of $135,000,000.

What was Endospan's last funding round before its acquisition?

In July 2024, Endospan received $25,000,000 in Debt Financing from Artivion.

When did Endospan receive FDA Breakthrough Device Designation for its NEXUS Aortic Arch Stent Graft System?

Endospan received FDA Breakthrough Device Designation for its NEXUS Aortic Arch Stent Graft System in April 2020.

When did Endospan secure CE Mark approval for its Nexus stent graft system?

Endospan secured CE Mark approval for its Nexus stent graft system for branched endovascular repair in the aortic arch in March 2019.

How many employees does Endospan currently have?

Endospan has 51-200 employees.

Who are the founders of Endospan?

Endospan was founded by Alon Shalev and Rafi Benary.

What was a significant debt financing round for Endospan in 2019?

In September 2019, Endospan secured $15,000,000 in Debt Financing, led by CryoLife.

Team · 2

Alon Shalev

Founder · Founder

Rafi Benary

Founder · Co-Founder

Sectors & technology

Highlights

Tags